SlideShare una empresa de Scribd logo
1 de 88
Descargar para leer sin conexión
Dr. RAHI KIRAN.B
SR NEUROLOGY
GOVT MEDICAL COLLEGE, KOTA
 Classification
 Red flag signs
 Diagnostic criteria
 Phenotypic spectrum
 Investigations
 Novel biomarkers
 Treatment
 Future trends
 Common problem in neurology OPD
 Wide variety of sporadic / heredodegenerative syndromes
 80-85% -IPD
 Differentiation from other syndromes
 important in prognostication and management
Parkinson's  plus syndromes
 Progressive Supranuclear Palsy
 Multiple System Atrophy [(Shy-Dragger syn.) SND (MSAP) OPCA (MSAC)]
 Corticobasal Degeneration
 Dementia with Lewy Body Disease
 Accurate diagnosis is necessary to understand pathogenesis
 Two proteins mainly
 Alpha synuclein
- Pre synaptic protein
- Aggregates in cell body & neurons – lewy body & lewy neuritis- PD &
DLBD
- glial cytoplasmic inclusion in MSA
Parkinson's  plus syndromes
Parkinson's  plus syndromes
SYNUCLEINOPATHY TAUPATHY
Parkinson's  plus syndromes
 Steele et al—1964
 5% of parkinsonian pts
 male-to-female ratio is 1.5:1
 Commonly misdiagnosed as PD
 diagnosis is purely clinical
 always sporadic, few familial cases-
 The usual interval from initial symptom occurrence to the need for a cane or a walker is
3.1 years,
 confinement to a chair or bed is 8.2 years.
 median disease duration of 9.7 years
Postural Instability & EP Features :
 Falls—backward
 Rigidity –axial
 Hypophonic
 Widely based ataxic
 Frontal release signs
 Pseudobulbar palsy
 L-DOPA UNRESPONSIVENESS
 early signs- Slow vertical saccades and square wave jerks
 Reduced blink rate and apraxia of eyelid opening
 on doll’s eye maneuver, there is improved range
 Subcortical-type dementia
 Typical facies- “surprised look”
 advanced PSP - Complete ophthalmoparesis
Parkinson's  plus syndromes
Possible PSP(highly sensitive)
Mandatory inclusion criteria:
 Gradually progressive disorder
 Onset age 40 or later
 Either vertical supranuclear palsy or both slowing of vertical saccades
 Postural instability with falls within a year of disease onset
 No evidence of other diseases that could explain the foregoing features, as
indicated by exclusion criteria
Mandatory exclusion criteria:
 Recent history of encephalitis
 Alien limb syndrome
 Cortical sensory deficits
 Focal frontal or temporoparietal atrophy
 Hallucinations or delusions unrelated to dopaminergic
therapy
 Cortical dementia of Alzheimer type
 Prominent, early cerebellar symptoms
 Unexplained dysautonomia
NINDS–SPSP DIAGNOSTIC CRITERIA FOR PSP
Supportive features:
 symmetrical akinesia or rigidity
 proximal more than distal
 abnormal neck posture especially retrocollis
 poor or absent response of parkinsonism to levodopa
 early dysphagia and dysarthria
 early onset of cognitive impairment including two or more of: apathy,
impairment in abstract thought, decreased verbal fluency, utilisation or
imitation behaviour, or frontal release signs
NINDS–SPSP DIAGNOSTIC CRITERIA FOR PSP
Probable PSP(highly specific)
Mandatory inclusion criteria
 gradually progressive disorder
 onset age 40 or later
 vertical supranuclear palsy
 prominent postural instability with falls within a year of disease onset
 no evidence of other diseases that could explain the foregoing features,
as indicated by exclusion criteria
NINDS–SPSP DIAGNOSTIC CRITERIA FOR PSP
Definite PSP
Mandatory inclusion criteria:
 Clinically probable or possible PSP and
histopathological evidence of typical PSP
NINDS–SPSP DIAGNOSTIC CRITERIA FOR PSP
Parkinson's  plus syndromes
INVESTIGATIONS
 Clinical diagnosis
 MRI-
midbrain atrophy(appearance of a flat or concave profile -68% sensitivity and an 89%
specificity
Superior cerebellar peduncle atrophy.
“morning glory flower sign” and the “hummingbird sign” – Highly specific(100%) low
sensitivity (50% and 68.4%)
magnetic resonance parkinsonism index (MRPI) - sensitivity of 100%
and specificity of 99·2–100·0% for PSP-RS.
pons:midbrain ratio-
oPET – lowered glucose metabolism in the midbrain ,caudate, Thalamus of PSP
 MIBG is abnormal in PD because of postganglionic sympathetic denervation, but is
typically normal in PSP.
 IBZM SPECT assessing the postsynaptic receptors is abnormal in PSP and normal in
PD
 IBZM SPECT is abnormal in all Aps
 (DATscan) is abnormal in PD and all AP syndromes
INVESTIGATIONS
Parkinson's  plus syndromes
PATHOLOGY
 Neurofibrillary tangles are present in reticular formation and ocular motor nuclei.
 Tufted astrocytes (Gallyas-positive) -feature of PSP that differentiates other
tauopathies such as CBD (astrocytic plaques)
Parkinson's  plus syndromes
-CSF tau protein- CSF phospho-tau and total tau concentrations lower than AD
- 2–5 times increased neurofilament light chain concentrations in PSP
Novel diagnostic approaches and biomarkers
Treatment
 No effective symptomatic or neuroprotective treatments
 A trial of levodopa (up to 1 g/d) and amantadine (up to 450mg/d)
 Botulinum toxin injections can be used to treat levator inhibition,rigiditY, dystonia
 Serotonin reuptake inhibitors (SSRIs) may be used for apathy with no clear benefit.
 Supportive measures such as physiotherapy, walking aids, speech therapy and PEG
 A small study with Coenzyme Q10- no RCTstudy
 Recent large, double-blind studies with GSK-3b inhibitors (Tideglusib,
Davunetide) - failed.
 Tideglusib reduced the rate of brain atrophy in onestudy.
 Sporadic neurodegenerative disorder clinically any combination of parkinsonian,
autonomic, cerebellar, or pyramidal signs
 MSA is an a-synucleinopathy
 usually a sporadic disease; however, rarely, familial cases - mutations in COQ2
gene
 Prevalence of MSA - ranged from 1·9 to 4·9 cases per 100 000 people.
Clinical presentation :
 Affects both men and women
 sixth decade of life
 mean survival of 6–9 years.(upto 15yrs)
Main features –
 Autonomic failure
 Parkinsonism
 Cerebellar ataxia
 Pyramidal signs in any combination.
 Distinguished clinically–
1. Parkinsonian features predominate in 80% of patients (MSA-P
subtype),
2. Cerebellar ataxia is the main motor feature in 20% of patients (MSA-C
subtype).
 Both similar survival times.
 MSA-P - more rapid functional deterioration
 progressive akinesia and rigidity
 jerky postural tremor and tremor at rest.
 orofacial or craniocervical dystonia
 recurrent falls at disease onset are unusual .
 90% of the MSA-P pts- unresponsive to levodopa in the long term.
 gait ataxia
 scanning dysarthria
 cerebellar oculomotor disturbances.
 may be indistinguishable from other patients with idiopathic late onset cerebellar
ataxia
Dysautonomia :
 urogenital and orthostatic dysfunction.
 Early erectile dysfunction is nearly universal in men with MSA
 Female- genital insensitivity
 urinary incontinence or retention are common
Autonomic and urinary dysfunction :
 Features
 1. Orthostatic hypotension(68% of patients)
 2. Urinary incontinence or incomplete bladder emptying
Criteria
 Reduction of least 30mmHg or in diastolic blood pressure by at least 15 mm Hg
after 3 min of standing
 urinary incontinence (persistent, involuntary partial or total bladder emptying,
accompanied by erectile dysfunction in men) or both
Parkinsonism :initial feature in 46% of patients with MSA-P
A. Features
 1. Bradykinesia
 2. Rigidity
 3. Postural instability (not caused by primary visual, vestibular, cerebellar, or
proprioceptive dysfunction)
 4. Tremor (postural, resting or both)
B. Criteria
 Bradykinesia plus at least one of features 2–4
Cerebellar dysfunction :initial feature in 5%
A. Features
1. Gait ataxia
2. Ataxicdysarthria
3. Limb ataxia
4. Sustained gaze-evoked nystagmus
Criteria
 Gait ataxia plus at least one of features 2–4
Corticospinal tract dysfunction
A. Features
1. Extensor plantar responses with hyper-reflexia
Criteria
 no corticospinal tract features are used in defining the diagnosis of MSA
 prominent and severe spasticity should raise suspicion for an
alternative diagnosis
exclusion criteria:
 Symptomatic onset <30 years/>75YRS of age
 Family history of a similar disorder
 Systemic disease or other identifiable causes
 Hallucinations unrelated to medication
 Dementia
exclusion criteria:
 Prominent slowing of vertical saccades or vertical supranuclear gaze palsy
 Evidence of focal cortical dysfunction
 Laboratory investigation- Metabolic, molecular genetic and imaging evidence of an
alternative cause of features
 Possible MSA
 A sporadic, progressive, adult (>30y) with onset disease* characterized by the following:
 Parkinsonism or cerebellar syndrome
 At least 1 feature of autonomic or urogenital dysfunction
 At least 1 additional feature
 Probable MSA
 A sporadic, progressive, adult (>30y) with onset disease* characterized by the following:
 Autonomic failure involving urinary dysfunction
 Poorly levodopa-responsive parkinsonism or
 cerebellar dysfunction
 Definitive MSA
 A sporadic, progressive, adult (>30y) with onset disease pathologically confirmed by
presence of high density GCIs in association with degenerative changes in
striatonigral and olivopontocerebellar pathways
 Pyramidal signs
 Orofacial dystonia or dyskinesias
 dyskinesia mainly affecting orofacial muscles
 Axial dystonia -Pisa syndrome (subacute axial dystonia with a severe
tonic lateral flexion of the trunk, head, and neck)
 early severe camptocormia
MSA - Additional features
 Jerky tremor
 Dysarthria- Atypical, irregular and severely hypophonic
 Dysphagia within 5 years of motor onset
 Neuropsychiatric features - • Depression (41%) • Hallucinations (5·5%)
• Dementia (4·5%) • Insomnia (19%)
• Daytime sleepiness (17%) • Restless legs (10%)
MSA - Additional features
 Atrophy on MRI of putamen, middle cerebellar peduncle, pons, or cerebellum
 Hypometabolism on FDG-PET in putamen, brainstem, or cerebellum
Parkinson's  plus syndromes
Investigations
 Autonomic function tests
 Cardiovascular function test-within in 2-3 ys
 Standard urine analysis will exclude infection.
 The residual volume –usg,cystometry ,UDS
MSA
IMAGING
 MRI
- Hot cross burn sign- mcp/pons- MSA-c
- Putaminal rim- MSA-p
The slight hyperintensity of the lateral margin of the putamen on T2-
weighted MRI is a characteristic finding in patients with MSA involving the
extrapyramidal system
Trace (D)-DW MRI -MSA-P-anterior putamen
MSA-C-cerebellum and middle cerebellar peduncle
Parkinson's  plus syndromes
.
- DAT scan abnormal in all MSA, PSP, and PD
- MIBG scintigraphy abnormal in PD, normal in MSA
 IBZM SPECT is normal in PD,abnormal in MSA(but also in PSP and CBD)
PET- The caudateputamen index- lower in patients with MSA than in PD
CSF mean a-synuclein levels from PD (70% sensitivity, 53% specificity)
 a-synuclein and phosphorylated t/total t could differentiate PD from MSA -sensitivity
of 90% & specificity of 71%
 Flt3 ligand, a cytokine
PD and MSA with a sensitivity of 99% and a specificity of 95%.
COQ2, a gene that encodes coenzyme Q10,
TREATMENT
 Symptomatic
 PD- L-dopa/ dopa agonists- cranio cervical dystonia postural hypotension
Amantidine- gait disturbances
 Orthostatic hypotension-
high salt, fludrocortisone,midodrine
 Urinary dysfunction
- UDS
-Neurogenic bladder- Oxybutinin or Tolderotidne
 Erectile dysfunction-
- sildenafil
-intracavernosal inj. Or penile implants
 Depession
- SSRI/TCA
Promising studies
- Rasagiline
- Intrarterial/IV - autologous stem cells
- Future trials
- Alpha synuclein targeting antibodies
TREATMENT
Sixth to eighth decades of life - mean age 63 years
. Sporadic disease , 4–6% of parkinsonism.
Clinical presentations
 Five initial presentations
 The most common presentation (55%) -“useless arm” (ie, a rigid, dystonic,
akinetic, or apraxic arm),
 gait disorder (27%)
 prominent sensory symptoms
 isolated speech disturbance
 behavioural disturbance
Motor (asymmetric)
Limb clumsiness
Bradykinesia/Akinesia
Rigidity
Tremor (action/postural)
Myoclonus
Limb dystonia
Blepharospasm
Choreoathetoid movements
Speech abnormalities
Gait disorder
Higher cortical functions
 Apraxia
 Dementia
 Alien-limb phenomenon
 Aphasia
 Frontal-lobe-release signs
 Cortical sensory abnormalities
 Depression
 apathy
 Anxiety Irritability
 Disinhibition, Delusions,Obsessive compulsive disorder
Inclusion criteria (one of A orB)
A) Rigidity (easily detectable without reinforcement) and one cortical sign:
 apraxia
 cortical sensory loss
 alien-limb phenomenon
B) Asymmetric rigidity, dystonia (focal in limb; present at rest at onset),
 focal reflex myoclonus (spreads beyond stimulated digits
Exclusion criteria
 Early dementia (will exclude some patients)
 Early vertical gaze palsy
 Rest tremor
 Severe autonomic disturbances
 Sustained responsiveness to levodopa
 Lesions on imaging studies indicate another
pathological process
 Variable degrees of focal or lateralised cognitive dysfunction,
with relative preservation of learning and memory on neuropsychometric testing
 Focal or asymmetric atrophy on CT or MRI imaging, typically in perifrontal cortex
 Focal or asymmetric hypoperfusion on SPECT or PET, typically maximal in
parietofrontal cortex with or without basal ganglia involvement
investigations
PHENOTYPIC SPECTRUM
 Classic CBD phenotype- CBS
 CBD- a/w FTD,PSP,PPA
 Imaging
asymmetric frontal, and parietal cortical atrophy becomes evident with dilatation
of the lateral ventricle(temporal/parietal cortex (the latter pattern is seen in
dementia of the Alzheimer type)
 Dopamine transporter SPECT- abnormal
- differentiate them from those with Alzheimer’s and Pick’s diseases (in whom this
scan is typically normal) early in the course of the disease.
 FDG-PET
- Asymmetric reduction in fronto parietalregions
LP & jejunal biopsy- Whipple disease
 The R2 component of the blink reflex recovery cycle (R2 BRRC) appears to be a useful tool
to distinguish progressive supranuclear palsy (PSP) from corticobasal degeneration (CBD)
 4-repeat-tau aggregates - neocortex in CBD, brainstem in PSP
TREATMENT
 L-dopa trial (upto 1 gm/d)/Amantadine- PD symptoms
 Valproate, Levetiracetam- myoclonus
 Botox inj- dystonic hand
 antioxidants or vitamin E if the patient has memory loss
 Palliative rx
 Dementia -not occur in the early stages ,usually evident with progression.
 Deficits on tests of attention, executive function, and visuospatial ability may
be especially prominent.
 Two core features are sufficient for a diagnosis of probable, one for
possible DLB
 Fluctuating cognition with pronounced variations in attention and
alertness
 Recurrent visual hallucinations that are typically well formed and detailed
 features of parkinsonism
 REM sleep behavior disorder
 Severe neuroleptic sensitivity
 Low dopamine transporter uptake in basal ganglia demonstrated by
SPECT or PET imaging
 one or more of these + one or more core features, - probable DLB .
 In the absence of any core features, one or more
suggestive features - possible DLB.
 Probable DLB should not be diagnosed on the basis of suggestive features alone.
 Repeated falls and syncope, Transient unexplained loss of consciousness
 Severe autonomic dysfunction
 Hallucinations in other modalities
 Depression
 Relative preservation of medial temporal lobe structures on CT/MRI scan
 Generalized low uptake on SPECT/PET perfusion scan with reduced
occipital activity
 Prominent slow wave activity on EEG with temporal lobe transient sharp waves
 If -CVA evident as focal neurologic signs or on brain imaging
 In the presence of any other physical illness or brain disorder sufficient to
account in part or in total for the clinical picture
 If parkinsonism only appears for the first time at a stage of severe dementia
 Diagnosed when dementia occurs before or concurrently with parkinsonism (if it is
present).
 Parkinson disease dementia (PDD) - dementia that occurs in the context of well-
established Parkinson disease.
 the 1-year rule between the onset of dementia and parkinsonism – DLB .
 less hippocampal atrophy - DLB
 SPECT & PET - decreased occipital lobe blood flow – DLB > AD
relative preservation of the posterior cingulate gyrus (cingulate island
sign) - DLB > AD
 SPECT scanning studies in DLB patients :
 Visual hallucinations - Were related to hypoperfusion of the parietal and occipital
association cortices
 Misidentifications - Were related to hypoperfusion of the limbic-paralimbic structures
 Delusions - Were related to hyperperfusion of the frontal cortices
 CSF
 Tau – DLB < AD
 beta amyloid are lower than normal in DLB, AD
 LBCRS - Lewy body composite risk score - help determine whether Lewy body
pathology is contributing to dementia.
 Motor parkinsonism-mild hallucinations and agitation may not require medical
treatment.
-Levodopa at low doses & titrate up.
-Anticholinergics should be avoided.
 Neuropsychiatric symptoms.--cholinesterase inhibitors (CHEIs) or atypical
antipsychotic ,
modafinil initially had a positive effect , but didn't last long.
 memantine improves cognitive function and neuropsychiatric features in
patients with DLB.
Parkinson's  plus syndromes
Parkinson's  plus syndromes
 prion hypothesis - recently
Parkinson's  plus syndromes
 davunetide , tideglusib - failed
 droxidopa - orthostatic hypotension – failed
 losartan - supine hypertension - failed
SUMMARY
 Careful clinical examination
 AP mimickers
 There are currently no biomarkers available.
 There are currently no neuroprotective treatments available.
 symptomatic and supportive treatments with usually no sustained effect.
 Further research required
THANK YOU
Parkinson's  plus syndromes
Parkinson's  plus syndromes
Parkinson's  plus syndromes
magnetic resonance
parkinsonism index (MRPI) -(P / M) x (MCP / SCP)
MCP = width of middle cerebellar peduncle
SCP = width of superior cerebellar peduncle
P = area of pons in midsagittal plane
M = area of midbrain in midsagittal plane
A value of more than 13.55 indicates an abnormal result, and
strongly suggests that these patients will go on to develop PSP.
Misdiagnosis PD with AP , as well as FTD,AD,PPA
Mimickers of AtypicalPD Eg: SCAS/ FTAX- mimic
MSA
Neimann Pick C,CTX,prion d/s,mitochondrial- mimic AP phenotype
- Age of onset
- Tempo of progression
- Family history
- Clinical exam + associated features

Más contenido relacionado

La actualidad más candente

Non compressive myelopathy
Non compressive myelopathyNon compressive myelopathy
Non compressive myelopathyHirdesh Chawla
 
Sensory ataxia
Sensory ataxiaSensory ataxia
Sensory ataxiaSusanth Mj
 
Approach to dystonia
Approach to dystoniaApproach to dystonia
Approach to dystoniaNeurologyKota
 
Paraparesis biplave nams
Paraparesis biplave namsParaparesis biplave nams
Paraparesis biplave namsbiplave karki
 
Ataxia
AtaxiaAtaxia
AtaxiaFizio
 
Acute disseminated encephalomyelitis
Acute disseminated encephalomyelitis Acute disseminated encephalomyelitis
Acute disseminated encephalomyelitis Reyad Al_Faky
 
Hereditary neuropathies
Hereditary neuropathies  Hereditary neuropathies
Hereditary neuropathies NeurologyKota
 
Parkinson plus syndrome
Parkinson plus syndromeParkinson plus syndrome
Parkinson plus syndromeAhmad Shahir
 
Young-Onset Parkinson Disease
Young-Onset Parkinson Disease Young-Onset Parkinson Disease
Young-Onset Parkinson Disease Ade Wijaya
 
Ataxia 130514030409-phpapp01
Ataxia 130514030409-phpapp01Ataxia 130514030409-phpapp01
Ataxia 130514030409-phpapp01Indhu Reddy
 
Approach to peripheral neuropathy
Approach to peripheral neuropathyApproach to peripheral neuropathy
Approach to peripheral neuropathyNeurologyKota
 
Restless leg syndrome
Restless leg syndromeRestless leg syndrome
Restless leg syndromeNeurologyKota
 

La actualidad más candente (20)

Non compressive myelopathy
Non compressive myelopathyNon compressive myelopathy
Non compressive myelopathy
 
Myoclonus
MyoclonusMyoclonus
Myoclonus
 
Tremors
TremorsTremors
Tremors
 
Spinocerebellar ataxia
Spinocerebellar ataxiaSpinocerebellar ataxia
Spinocerebellar ataxia
 
Sensory ataxia
Sensory ataxiaSensory ataxia
Sensory ataxia
 
Approach to dystonia
Approach to dystoniaApproach to dystonia
Approach to dystonia
 
Tremor
TremorTremor
Tremor
 
Paraparesis biplave nams
Paraparesis biplave namsParaparesis biplave nams
Paraparesis biplave nams
 
Ataxia
AtaxiaAtaxia
Ataxia
 
Spinocerebellar ataxia
Spinocerebellar ataxiaSpinocerebellar ataxia
Spinocerebellar ataxia
 
Approach to Ataxia
Approach to AtaxiaApproach to Ataxia
Approach to Ataxia
 
Acute disseminated encephalomyelitis
Acute disseminated encephalomyelitis Acute disseminated encephalomyelitis
Acute disseminated encephalomyelitis
 
Hereditary neuropathies
Hereditary neuropathies  Hereditary neuropathies
Hereditary neuropathies
 
Parkinson plus syndrome
Parkinson plus syndromeParkinson plus syndrome
Parkinson plus syndrome
 
Young-Onset Parkinson Disease
Young-Onset Parkinson Disease Young-Onset Parkinson Disease
Young-Onset Parkinson Disease
 
Ataxia 130514030409-phpapp01
Ataxia 130514030409-phpapp01Ataxia 130514030409-phpapp01
Ataxia 130514030409-phpapp01
 
Approach to peripheral neuropathy
Approach to peripheral neuropathyApproach to peripheral neuropathy
Approach to peripheral neuropathy
 
Restless leg syndrome
Restless leg syndromeRestless leg syndrome
Restless leg syndrome
 
Transverse myelitis
Transverse myelitisTransverse myelitis
Transverse myelitis
 
Diabetic POLYNEUROPATHY
Diabetic POLYNEUROPATHYDiabetic POLYNEUROPATHY
Diabetic POLYNEUROPATHY
 

Similar a Parkinson's plus syndromes

Parkinsonism syndromes with differential diagnosis
Parkinsonism syndromes with differential diagnosisParkinsonism syndromes with differential diagnosis
Parkinsonism syndromes with differential diagnosisVaibhav Kumar Somvanshi
 
Parkinson Plus Seminar PPT.pptx
Parkinson Plus Seminar PPT.pptxParkinson Plus Seminar PPT.pptx
Parkinson Plus Seminar PPT.pptxSapnaDhote1
 
Parkinsons Disease
Parkinsons DiseaseParkinsons Disease
Parkinsons Diseasetest
 
Psp - Progressive Supranuclear Palsy
Psp - Progressive Supranuclear PalsyPsp - Progressive Supranuclear Palsy
Psp - Progressive Supranuclear PalsyJaber Samer
 
parkinsonism-180214104126.pdf
parkinsonism-180214104126.pdfparkinsonism-180214104126.pdf
parkinsonism-180214104126.pdfJunaid Khan
 
autoimmuneencephalitisppt-180103161321 2.pdf
autoimmuneencephalitisppt-180103161321 2.pdfautoimmuneencephalitisppt-180103161321 2.pdf
autoimmuneencephalitisppt-180103161321 2.pdfabhimittal8
 
Autoimmune encephalitis ppt
Autoimmune encephalitis pptAutoimmune encephalitis ppt
Autoimmune encephalitis pptSachin Adukia
 
Parkinsonism.ppt
Parkinsonism.pptParkinsonism.ppt
Parkinsonism.pptShama
 
Approach to parkinsonism
Approach to parkinsonismApproach to parkinsonism
Approach to parkinsonismNeurologyKota
 
Approach to parkinsonism
Approach to parkinsonismApproach to parkinsonism
Approach to parkinsonismNeurologyKota
 
Parkinson's disease n management
Parkinson's disease n managementParkinson's disease n management
Parkinson's disease n managementDr. Rupendra Bharti
 

Similar a Parkinson's plus syndromes (20)

Parkinsonism syndromes with differential diagnosis
Parkinsonism syndromes with differential diagnosisParkinsonism syndromes with differential diagnosis
Parkinsonism syndromes with differential diagnosis
 
Parkinson Plus Seminar PPT.pptx
Parkinson Plus Seminar PPT.pptxParkinson Plus Seminar PPT.pptx
Parkinson Plus Seminar PPT.pptx
 
Parkinsons Disease
Parkinsons DiseaseParkinsons Disease
Parkinsons Disease
 
Psp - Progressive Supranuclear Palsy
Psp - Progressive Supranuclear PalsyPsp - Progressive Supranuclear Palsy
Psp - Progressive Supranuclear Palsy
 
Parkinson’s disease
Parkinson’s diseaseParkinson’s disease
Parkinson’s disease
 
Parkinson Disease
Parkinson DiseaseParkinson Disease
Parkinson Disease
 
parkinsonism-180214104126.pdf
parkinsonism-180214104126.pdfparkinsonism-180214104126.pdf
parkinsonism-180214104126.pdf
 
Parkinsonism
ParkinsonismParkinsonism
Parkinsonism
 
autoimmuneencephalitisppt-180103161321 2.pdf
autoimmuneencephalitisppt-180103161321 2.pdfautoimmuneencephalitisppt-180103161321 2.pdf
autoimmuneencephalitisppt-180103161321 2.pdf
 
Autoimmune encephalitis ppt
Autoimmune encephalitis pptAutoimmune encephalitis ppt
Autoimmune encephalitis ppt
 
Parkinsonism.ppt
Parkinsonism.pptParkinsonism.ppt
Parkinsonism.ppt
 
Parkinson's Disease
Parkinson's DiseaseParkinson's Disease
Parkinson's Disease
 
Parkinsonism
Parkinsonism Parkinsonism
Parkinsonism
 
Approach to parkinsonism
Approach to parkinsonismApproach to parkinsonism
Approach to parkinsonism
 
Approach to parkinsonism
Approach to parkinsonismApproach to parkinsonism
Approach to parkinsonism
 
Approach to ataxia
Approach to ataxiaApproach to ataxia
Approach to ataxia
 
Parkinson's disease n management
Parkinson's disease n managementParkinson's disease n management
Parkinson's disease n management
 
PARKINSONIAN DISORDERS.pptx
PARKINSONIAN DISORDERS.pptxPARKINSONIAN DISORDERS.pptx
PARKINSONIAN DISORDERS.pptx
 
Antiparkinsons
AntiparkinsonsAntiparkinsons
Antiparkinsons
 
Antiparkinsons
AntiparkinsonsAntiparkinsons
Antiparkinsons
 

Más de NeurologyKota

CONCEPT OF NODOPATHIES AND PARANODOPATHIES.pptx
CONCEPT OF NODOPATHIES AND PARANODOPATHIES.pptxCONCEPT OF NODOPATHIES AND PARANODOPATHIES.pptx
CONCEPT OF NODOPATHIES AND PARANODOPATHIES.pptxNeurologyKota
 
NEUROLOGICAL SCALES FOR ASSESSMENT OF CONSCIOUSNESS.pptx
NEUROLOGICAL SCALES FOR ASSESSMENT OF CONSCIOUSNESS.pptxNEUROLOGICAL SCALES FOR ASSESSMENT OF CONSCIOUSNESS.pptx
NEUROLOGICAL SCALES FOR ASSESSMENT OF CONSCIOUSNESS.pptxNeurologyKota
 
LOCALISATION OF LESION CAUSING COMA.pptx
LOCALISATION OF LESION CAUSING COMA.pptxLOCALISATION OF LESION CAUSING COMA.pptx
LOCALISATION OF LESION CAUSING COMA.pptxNeurologyKota
 
TREADMILL For_BRAIN_Dr Bharat Bhushan sir.pptx
TREADMILL For_BRAIN_Dr Bharat Bhushan sir.pptxTREADMILL For_BRAIN_Dr Bharat Bhushan sir.pptx
TREADMILL For_BRAIN_Dr Bharat Bhushan sir.pptxNeurologyKota
 
DUAL AND TRIPLE ANTITHROMBOTIC THERAPY FOR SECONDARY STROKE [Autosaved].pptx
DUAL AND TRIPLE ANTITHROMBOTIC THERAPY FOR SECONDARY STROKE [Autosaved].pptxDUAL AND TRIPLE ANTITHROMBOTIC THERAPY FOR SECONDARY STROKE [Autosaved].pptx
DUAL AND TRIPLE ANTITHROMBOTIC THERAPY FOR SECONDARY STROKE [Autosaved].pptxNeurologyKota
 
SMART WEARABLE DEVICES IN NEUROLOGY new.pptx
SMART WEARABLE DEVICES IN NEUROLOGY new.pptxSMART WEARABLE DEVICES IN NEUROLOGY new.pptx
SMART WEARABLE DEVICES IN NEUROLOGY new.pptxNeurologyKota
 
ASSESSMENT OF AUTONOMIC FUNCTION TEST.pptx
ASSESSMENT OF AUTONOMIC FUNCTION TEST.pptxASSESSMENT OF AUTONOMIC FUNCTION TEST.pptx
ASSESSMENT OF AUTONOMIC FUNCTION TEST.pptxNeurologyKota
 
TRANSCRANIAL DOPPLER (1).pptx
TRANSCRANIAL DOPPLER (1).pptxTRANSCRANIAL DOPPLER (1).pptx
TRANSCRANIAL DOPPLER (1).pptxNeurologyKota
 
INTRACEREBRAL HEMORRHAGE IN YOUNG ADULTS.pptx
INTRACEREBRAL HEMORRHAGE IN YOUNG ADULTS.pptxINTRACEREBRAL HEMORRHAGE IN YOUNG ADULTS.pptx
INTRACEREBRAL HEMORRHAGE IN YOUNG ADULTS.pptxNeurologyKota
 
EPILEPTIC ENCEPHALOPATHY
 EPILEPTIC ENCEPHALOPATHY  EPILEPTIC ENCEPHALOPATHY
EPILEPTIC ENCEPHALOPATHY NeurologyKota
 
Domain Assessment in Dementia.pptx
Domain Assessment in Dementia.pptxDomain Assessment in Dementia.pptx
Domain Assessment in Dementia.pptxNeurologyKota
 
Young Onset Dementia.pptx
Young Onset Dementia.pptxYoung Onset Dementia.pptx
Young Onset Dementia.pptxNeurologyKota
 
NEWER INSIGHT IN FUNCTIONAL NEUROLOGICAL DISORDER
NEWER INSIGHT IN FUNCTIONAL NEUROLOGICAL DISORDER NEWER INSIGHT IN FUNCTIONAL NEUROLOGICAL DISORDER
NEWER INSIGHT IN FUNCTIONAL NEUROLOGICAL DISORDER NeurologyKota
 
Hyperthermic syndrome in ICU and their management.pptx
Hyperthermic syndrome in ICU and their management.pptxHyperthermic syndrome in ICU and their management.pptx
Hyperthermic syndrome in ICU and their management.pptxNeurologyKota
 
Entrapment Syndromes of Lower Limb.pptx
Entrapment Syndromes of Lower Limb.pptxEntrapment Syndromes of Lower Limb.pptx
Entrapment Syndromes of Lower Limb.pptxNeurologyKota
 
MOG and IgG-4 related Neurological manifestation.pptx
MOG and IgG-4 related Neurological manifestation.pptxMOG and IgG-4 related Neurological manifestation.pptx
MOG and IgG-4 related Neurological manifestation.pptxNeurologyKota
 

Más de NeurologyKota (20)

CONCEPT OF NODOPATHIES AND PARANODOPATHIES.pptx
CONCEPT OF NODOPATHIES AND PARANODOPATHIES.pptxCONCEPT OF NODOPATHIES AND PARANODOPATHIES.pptx
CONCEPT OF NODOPATHIES AND PARANODOPATHIES.pptx
 
NEUROLOGICAL SCALES FOR ASSESSMENT OF CONSCIOUSNESS.pptx
NEUROLOGICAL SCALES FOR ASSESSMENT OF CONSCIOUSNESS.pptxNEUROLOGICAL SCALES FOR ASSESSMENT OF CONSCIOUSNESS.pptx
NEUROLOGICAL SCALES FOR ASSESSMENT OF CONSCIOUSNESS.pptx
 
LOCALISATION OF LESION CAUSING COMA.pptx
LOCALISATION OF LESION CAUSING COMA.pptxLOCALISATION OF LESION CAUSING COMA.pptx
LOCALISATION OF LESION CAUSING COMA.pptx
 
TREADMILL For_BRAIN_Dr Bharat Bhushan sir.pptx
TREADMILL For_BRAIN_Dr Bharat Bhushan sir.pptxTREADMILL For_BRAIN_Dr Bharat Bhushan sir.pptx
TREADMILL For_BRAIN_Dr Bharat Bhushan sir.pptx
 
REMOTE ROBOTIC.pptx
REMOTE ROBOTIC.pptxREMOTE ROBOTIC.pptx
REMOTE ROBOTIC.pptx
 
DUAL AND TRIPLE ANTITHROMBOTIC THERAPY FOR SECONDARY STROKE [Autosaved].pptx
DUAL AND TRIPLE ANTITHROMBOTIC THERAPY FOR SECONDARY STROKE [Autosaved].pptxDUAL AND TRIPLE ANTITHROMBOTIC THERAPY FOR SECONDARY STROKE [Autosaved].pptx
DUAL AND TRIPLE ANTITHROMBOTIC THERAPY FOR SECONDARY STROKE [Autosaved].pptx
 
SMART WEARABLE DEVICES IN NEUROLOGY new.pptx
SMART WEARABLE DEVICES IN NEUROLOGY new.pptxSMART WEARABLE DEVICES IN NEUROLOGY new.pptx
SMART WEARABLE DEVICES IN NEUROLOGY new.pptx
 
ASSESSMENT OF AUTONOMIC FUNCTION TEST.pptx
ASSESSMENT OF AUTONOMIC FUNCTION TEST.pptxASSESSMENT OF AUTONOMIC FUNCTION TEST.pptx
ASSESSMENT OF AUTONOMIC FUNCTION TEST.pptx
 
TRANSCRANIAL DOPPLER (1).pptx
TRANSCRANIAL DOPPLER (1).pptxTRANSCRANIAL DOPPLER (1).pptx
TRANSCRANIAL DOPPLER (1).pptx
 
INTRACEREBRAL HEMORRHAGE IN YOUNG ADULTS.pptx
INTRACEREBRAL HEMORRHAGE IN YOUNG ADULTS.pptxINTRACEREBRAL HEMORRHAGE IN YOUNG ADULTS.pptx
INTRACEREBRAL HEMORRHAGE IN YOUNG ADULTS.pptx
 
CAROTID WEB.pptx
CAROTID WEB.pptxCAROTID WEB.pptx
CAROTID WEB.pptx
 
CNS IRIS.pptx
CNS IRIS.pptxCNS IRIS.pptx
CNS IRIS.pptx
 
EPILEPTIC ENCEPHALOPATHY
 EPILEPTIC ENCEPHALOPATHY  EPILEPTIC ENCEPHALOPATHY
EPILEPTIC ENCEPHALOPATHY
 
Domain Assessment in Dementia.pptx
Domain Assessment in Dementia.pptxDomain Assessment in Dementia.pptx
Domain Assessment in Dementia.pptx
 
Young Onset Dementia.pptx
Young Onset Dementia.pptxYoung Onset Dementia.pptx
Young Onset Dementia.pptx
 
ENCEPHALOPATHY
ENCEPHALOPATHY ENCEPHALOPATHY
ENCEPHALOPATHY
 
NEWER INSIGHT IN FUNCTIONAL NEUROLOGICAL DISORDER
NEWER INSIGHT IN FUNCTIONAL NEUROLOGICAL DISORDER NEWER INSIGHT IN FUNCTIONAL NEUROLOGICAL DISORDER
NEWER INSIGHT IN FUNCTIONAL NEUROLOGICAL DISORDER
 
Hyperthermic syndrome in ICU and their management.pptx
Hyperthermic syndrome in ICU and their management.pptxHyperthermic syndrome in ICU and their management.pptx
Hyperthermic syndrome in ICU and their management.pptx
 
Entrapment Syndromes of Lower Limb.pptx
Entrapment Syndromes of Lower Limb.pptxEntrapment Syndromes of Lower Limb.pptx
Entrapment Syndromes of Lower Limb.pptx
 
MOG and IgG-4 related Neurological manifestation.pptx
MOG and IgG-4 related Neurological manifestation.pptxMOG and IgG-4 related Neurological manifestation.pptx
MOG and IgG-4 related Neurological manifestation.pptx
 

Último

Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communicationskatiequigley33
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Peter Embi
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Vaikunthan Rajaratnam
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.pptRamDBawankar1
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfHongBiThi1
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...Sujoy Dasgupta
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectiondrhanifmohdali
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationMedicoseAcademics
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionkrishnareddy157915
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptxNIKITA BHUTE
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE Mamatha Lakka
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.aarjukhadka22
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptPradnya Wadekar
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024EwoutSteyerberg1
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisSujoy Dasgupta
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsMedicoseAcademics
 

Último (20)

Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communications
 
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.
 
Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissection
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung function
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.ppt
 
American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...
 
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosis
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functions
 

Parkinson's plus syndromes

  • 1. Dr. RAHI KIRAN.B SR NEUROLOGY GOVT MEDICAL COLLEGE, KOTA
  • 2.  Classification  Red flag signs  Diagnostic criteria  Phenotypic spectrum  Investigations  Novel biomarkers  Treatment  Future trends
  • 3.  Common problem in neurology OPD  Wide variety of sporadic / heredodegenerative syndromes  80-85% -IPD  Differentiation from other syndromes  important in prognostication and management
  • 5.  Progressive Supranuclear Palsy  Multiple System Atrophy [(Shy-Dragger syn.) SND (MSAP) OPCA (MSAC)]  Corticobasal Degeneration  Dementia with Lewy Body Disease
  • 6.  Accurate diagnosis is necessary to understand pathogenesis  Two proteins mainly  Alpha synuclein - Pre synaptic protein - Aggregates in cell body & neurons – lewy body & lewy neuritis- PD & DLBD - glial cytoplasmic inclusion in MSA
  • 11.  Steele et al—1964  5% of parkinsonian pts  male-to-female ratio is 1.5:1  Commonly misdiagnosed as PD  diagnosis is purely clinical  always sporadic, few familial cases-
  • 12.  The usual interval from initial symptom occurrence to the need for a cane or a walker is 3.1 years,  confinement to a chair or bed is 8.2 years.  median disease duration of 9.7 years
  • 13. Postural Instability & EP Features :  Falls—backward  Rigidity –axial  Hypophonic  Widely based ataxic  Frontal release signs  Pseudobulbar palsy  L-DOPA UNRESPONSIVENESS
  • 14.  early signs- Slow vertical saccades and square wave jerks  Reduced blink rate and apraxia of eyelid opening  on doll’s eye maneuver, there is improved range  Subcortical-type dementia  Typical facies- “surprised look”  advanced PSP - Complete ophthalmoparesis
  • 16. Possible PSP(highly sensitive) Mandatory inclusion criteria:  Gradually progressive disorder  Onset age 40 or later  Either vertical supranuclear palsy or both slowing of vertical saccades  Postural instability with falls within a year of disease onset  No evidence of other diseases that could explain the foregoing features, as indicated by exclusion criteria
  • 17. Mandatory exclusion criteria:  Recent history of encephalitis  Alien limb syndrome  Cortical sensory deficits  Focal frontal or temporoparietal atrophy  Hallucinations or delusions unrelated to dopaminergic therapy  Cortical dementia of Alzheimer type  Prominent, early cerebellar symptoms  Unexplained dysautonomia NINDS–SPSP DIAGNOSTIC CRITERIA FOR PSP
  • 18. Supportive features:  symmetrical akinesia or rigidity  proximal more than distal  abnormal neck posture especially retrocollis  poor or absent response of parkinsonism to levodopa  early dysphagia and dysarthria  early onset of cognitive impairment including two or more of: apathy, impairment in abstract thought, decreased verbal fluency, utilisation or imitation behaviour, or frontal release signs NINDS–SPSP DIAGNOSTIC CRITERIA FOR PSP
  • 19. Probable PSP(highly specific) Mandatory inclusion criteria  gradually progressive disorder  onset age 40 or later  vertical supranuclear palsy  prominent postural instability with falls within a year of disease onset  no evidence of other diseases that could explain the foregoing features, as indicated by exclusion criteria NINDS–SPSP DIAGNOSTIC CRITERIA FOR PSP
  • 20. Definite PSP Mandatory inclusion criteria:  Clinically probable or possible PSP and histopathological evidence of typical PSP NINDS–SPSP DIAGNOSTIC CRITERIA FOR PSP
  • 22. INVESTIGATIONS  Clinical diagnosis  MRI- midbrain atrophy(appearance of a flat or concave profile -68% sensitivity and an 89% specificity Superior cerebellar peduncle atrophy. “morning glory flower sign” and the “hummingbird sign” – Highly specific(100%) low sensitivity (50% and 68.4%) magnetic resonance parkinsonism index (MRPI) - sensitivity of 100% and specificity of 99·2–100·0% for PSP-RS. pons:midbrain ratio-
  • 23. oPET – lowered glucose metabolism in the midbrain ,caudate, Thalamus of PSP  MIBG is abnormal in PD because of postganglionic sympathetic denervation, but is typically normal in PSP.  IBZM SPECT assessing the postsynaptic receptors is abnormal in PSP and normal in PD  IBZM SPECT is abnormal in all Aps  (DATscan) is abnormal in PD and all AP syndromes INVESTIGATIONS
  • 25. PATHOLOGY  Neurofibrillary tangles are present in reticular formation and ocular motor nuclei.  Tufted astrocytes (Gallyas-positive) -feature of PSP that differentiates other tauopathies such as CBD (astrocytic plaques)
  • 27. -CSF tau protein- CSF phospho-tau and total tau concentrations lower than AD - 2–5 times increased neurofilament light chain concentrations in PSP Novel diagnostic approaches and biomarkers
  • 28. Treatment  No effective symptomatic or neuroprotective treatments  A trial of levodopa (up to 1 g/d) and amantadine (up to 450mg/d)  Botulinum toxin injections can be used to treat levator inhibition,rigiditY, dystonia  Serotonin reuptake inhibitors (SSRIs) may be used for apathy with no clear benefit.  Supportive measures such as physiotherapy, walking aids, speech therapy and PEG
  • 29.  A small study with Coenzyme Q10- no RCTstudy  Recent large, double-blind studies with GSK-3b inhibitors (Tideglusib, Davunetide) - failed.  Tideglusib reduced the rate of brain atrophy in onestudy.
  • 30.  Sporadic neurodegenerative disorder clinically any combination of parkinsonian, autonomic, cerebellar, or pyramidal signs  MSA is an a-synucleinopathy  usually a sporadic disease; however, rarely, familial cases - mutations in COQ2 gene  Prevalence of MSA - ranged from 1·9 to 4·9 cases per 100 000 people.
  • 31. Clinical presentation :  Affects both men and women  sixth decade of life  mean survival of 6–9 years.(upto 15yrs) Main features –  Autonomic failure  Parkinsonism  Cerebellar ataxia  Pyramidal signs in any combination.
  • 32.  Distinguished clinically– 1. Parkinsonian features predominate in 80% of patients (MSA-P subtype), 2. Cerebellar ataxia is the main motor feature in 20% of patients (MSA-C subtype).  Both similar survival times.  MSA-P - more rapid functional deterioration
  • 33.  progressive akinesia and rigidity  jerky postural tremor and tremor at rest.  orofacial or craniocervical dystonia  recurrent falls at disease onset are unusual .  90% of the MSA-P pts- unresponsive to levodopa in the long term.
  • 34.  gait ataxia  scanning dysarthria  cerebellar oculomotor disturbances.  may be indistinguishable from other patients with idiopathic late onset cerebellar ataxia
  • 35. Dysautonomia :  urogenital and orthostatic dysfunction.  Early erectile dysfunction is nearly universal in men with MSA  Female- genital insensitivity  urinary incontinence or retention are common
  • 36. Autonomic and urinary dysfunction :  Features  1. Orthostatic hypotension(68% of patients)  2. Urinary incontinence or incomplete bladder emptying Criteria  Reduction of least 30mmHg or in diastolic blood pressure by at least 15 mm Hg after 3 min of standing  urinary incontinence (persistent, involuntary partial or total bladder emptying, accompanied by erectile dysfunction in men) or both
  • 37. Parkinsonism :initial feature in 46% of patients with MSA-P A. Features  1. Bradykinesia  2. Rigidity  3. Postural instability (not caused by primary visual, vestibular, cerebellar, or proprioceptive dysfunction)  4. Tremor (postural, resting or both) B. Criteria  Bradykinesia plus at least one of features 2–4
  • 38. Cerebellar dysfunction :initial feature in 5% A. Features 1. Gait ataxia 2. Ataxicdysarthria 3. Limb ataxia 4. Sustained gaze-evoked nystagmus Criteria  Gait ataxia plus at least one of features 2–4
  • 39. Corticospinal tract dysfunction A. Features 1. Extensor plantar responses with hyper-reflexia Criteria  no corticospinal tract features are used in defining the diagnosis of MSA  prominent and severe spasticity should raise suspicion for an alternative diagnosis
  • 40. exclusion criteria:  Symptomatic onset <30 years/>75YRS of age  Family history of a similar disorder  Systemic disease or other identifiable causes  Hallucinations unrelated to medication  Dementia
  • 41. exclusion criteria:  Prominent slowing of vertical saccades or vertical supranuclear gaze palsy  Evidence of focal cortical dysfunction  Laboratory investigation- Metabolic, molecular genetic and imaging evidence of an alternative cause of features
  • 42.  Possible MSA  A sporadic, progressive, adult (>30y) with onset disease* characterized by the following:  Parkinsonism or cerebellar syndrome  At least 1 feature of autonomic or urogenital dysfunction  At least 1 additional feature  Probable MSA  A sporadic, progressive, adult (>30y) with onset disease* characterized by the following:  Autonomic failure involving urinary dysfunction  Poorly levodopa-responsive parkinsonism or  cerebellar dysfunction
  • 43.  Definitive MSA  A sporadic, progressive, adult (>30y) with onset disease pathologically confirmed by presence of high density GCIs in association with degenerative changes in striatonigral and olivopontocerebellar pathways
  • 44.  Pyramidal signs  Orofacial dystonia or dyskinesias  dyskinesia mainly affecting orofacial muscles  Axial dystonia -Pisa syndrome (subacute axial dystonia with a severe tonic lateral flexion of the trunk, head, and neck)  early severe camptocormia MSA - Additional features
  • 45.  Jerky tremor  Dysarthria- Atypical, irregular and severely hypophonic  Dysphagia within 5 years of motor onset  Neuropsychiatric features - • Depression (41%) • Hallucinations (5·5%) • Dementia (4·5%) • Insomnia (19%) • Daytime sleepiness (17%) • Restless legs (10%) MSA - Additional features
  • 46.  Atrophy on MRI of putamen, middle cerebellar peduncle, pons, or cerebellum  Hypometabolism on FDG-PET in putamen, brainstem, or cerebellum
  • 48. Investigations  Autonomic function tests  Cardiovascular function test-within in 2-3 ys  Standard urine analysis will exclude infection.  The residual volume –usg,cystometry ,UDS MSA
  • 49. IMAGING  MRI - Hot cross burn sign- mcp/pons- MSA-c - Putaminal rim- MSA-p The slight hyperintensity of the lateral margin of the putamen on T2- weighted MRI is a characteristic finding in patients with MSA involving the extrapyramidal system Trace (D)-DW MRI -MSA-P-anterior putamen MSA-C-cerebellum and middle cerebellar peduncle
  • 51. . - DAT scan abnormal in all MSA, PSP, and PD - MIBG scintigraphy abnormal in PD, normal in MSA  IBZM SPECT is normal in PD,abnormal in MSA(but also in PSP and CBD) PET- The caudateputamen index- lower in patients with MSA than in PD
  • 52. CSF mean a-synuclein levels from PD (70% sensitivity, 53% specificity)  a-synuclein and phosphorylated t/total t could differentiate PD from MSA -sensitivity of 90% & specificity of 71%  Flt3 ligand, a cytokine PD and MSA with a sensitivity of 99% and a specificity of 95%. COQ2, a gene that encodes coenzyme Q10,
  • 53. TREATMENT  Symptomatic  PD- L-dopa/ dopa agonists- cranio cervical dystonia postural hypotension Amantidine- gait disturbances  Orthostatic hypotension- high salt, fludrocortisone,midodrine  Urinary dysfunction - UDS -Neurogenic bladder- Oxybutinin or Tolderotidne  Erectile dysfunction- - sildenafil -intracavernosal inj. Or penile implants
  • 54.  Depession - SSRI/TCA Promising studies - Rasagiline - Intrarterial/IV - autologous stem cells - Future trials - Alpha synuclein targeting antibodies TREATMENT
  • 55. Sixth to eighth decades of life - mean age 63 years . Sporadic disease , 4–6% of parkinsonism.
  • 56. Clinical presentations  Five initial presentations  The most common presentation (55%) -“useless arm” (ie, a rigid, dystonic, akinetic, or apraxic arm),  gait disorder (27%)  prominent sensory symptoms  isolated speech disturbance  behavioural disturbance
  • 57. Motor (asymmetric) Limb clumsiness Bradykinesia/Akinesia Rigidity Tremor (action/postural) Myoclonus Limb dystonia Blepharospasm Choreoathetoid movements Speech abnormalities Gait disorder
  • 58. Higher cortical functions  Apraxia  Dementia  Alien-limb phenomenon  Aphasia  Frontal-lobe-release signs  Cortical sensory abnormalities  Depression  apathy  Anxiety Irritability  Disinhibition, Delusions,Obsessive compulsive disorder
  • 59. Inclusion criteria (one of A orB) A) Rigidity (easily detectable without reinforcement) and one cortical sign:  apraxia  cortical sensory loss  alien-limb phenomenon B) Asymmetric rigidity, dystonia (focal in limb; present at rest at onset),  focal reflex myoclonus (spreads beyond stimulated digits
  • 60. Exclusion criteria  Early dementia (will exclude some patients)  Early vertical gaze palsy  Rest tremor  Severe autonomic disturbances  Sustained responsiveness to levodopa  Lesions on imaging studies indicate another pathological process
  • 61.  Variable degrees of focal or lateralised cognitive dysfunction, with relative preservation of learning and memory on neuropsychometric testing  Focal or asymmetric atrophy on CT or MRI imaging, typically in perifrontal cortex  Focal or asymmetric hypoperfusion on SPECT or PET, typically maximal in parietofrontal cortex with or without basal ganglia involvement investigations
  • 62. PHENOTYPIC SPECTRUM  Classic CBD phenotype- CBS  CBD- a/w FTD,PSP,PPA
  • 63.  Imaging asymmetric frontal, and parietal cortical atrophy becomes evident with dilatation of the lateral ventricle(temporal/parietal cortex (the latter pattern is seen in dementia of the Alzheimer type)  Dopamine transporter SPECT- abnormal - differentiate them from those with Alzheimer’s and Pick’s diseases (in whom this scan is typically normal) early in the course of the disease.
  • 64.  FDG-PET - Asymmetric reduction in fronto parietalregions LP & jejunal biopsy- Whipple disease
  • 65.  The R2 component of the blink reflex recovery cycle (R2 BRRC) appears to be a useful tool to distinguish progressive supranuclear palsy (PSP) from corticobasal degeneration (CBD)  4-repeat-tau aggregates - neocortex in CBD, brainstem in PSP
  • 66. TREATMENT  L-dopa trial (upto 1 gm/d)/Amantadine- PD symptoms  Valproate, Levetiracetam- myoclonus  Botox inj- dystonic hand  antioxidants or vitamin E if the patient has memory loss  Palliative rx
  • 67.  Dementia -not occur in the early stages ,usually evident with progression.  Deficits on tests of attention, executive function, and visuospatial ability may be especially prominent.
  • 68.  Two core features are sufficient for a diagnosis of probable, one for possible DLB  Fluctuating cognition with pronounced variations in attention and alertness  Recurrent visual hallucinations that are typically well formed and detailed  features of parkinsonism
  • 69.  REM sleep behavior disorder  Severe neuroleptic sensitivity  Low dopamine transporter uptake in basal ganglia demonstrated by SPECT or PET imaging  one or more of these + one or more core features, - probable DLB .  In the absence of any core features, one or more suggestive features - possible DLB.  Probable DLB should not be diagnosed on the basis of suggestive features alone.
  • 70.  Repeated falls and syncope, Transient unexplained loss of consciousness  Severe autonomic dysfunction  Hallucinations in other modalities  Depression  Relative preservation of medial temporal lobe structures on CT/MRI scan  Generalized low uptake on SPECT/PET perfusion scan with reduced occipital activity  Prominent slow wave activity on EEG with temporal lobe transient sharp waves
  • 71.  If -CVA evident as focal neurologic signs or on brain imaging  In the presence of any other physical illness or brain disorder sufficient to account in part or in total for the clinical picture  If parkinsonism only appears for the first time at a stage of severe dementia
  • 72.  Diagnosed when dementia occurs before or concurrently with parkinsonism (if it is present).  Parkinson disease dementia (PDD) - dementia that occurs in the context of well- established Parkinson disease.  the 1-year rule between the onset of dementia and parkinsonism – DLB .
  • 73.  less hippocampal atrophy - DLB
  • 74.  SPECT & PET - decreased occipital lobe blood flow – DLB > AD relative preservation of the posterior cingulate gyrus (cingulate island sign) - DLB > AD  SPECT scanning studies in DLB patients :  Visual hallucinations - Were related to hypoperfusion of the parietal and occipital association cortices  Misidentifications - Were related to hypoperfusion of the limbic-paralimbic structures  Delusions - Were related to hyperperfusion of the frontal cortices
  • 75.  CSF  Tau – DLB < AD  beta amyloid are lower than normal in DLB, AD  LBCRS - Lewy body composite risk score - help determine whether Lewy body pathology is contributing to dementia.
  • 76.  Motor parkinsonism-mild hallucinations and agitation may not require medical treatment. -Levodopa at low doses & titrate up. -Anticholinergics should be avoided.  Neuropsychiatric symptoms.--cholinesterase inhibitors (CHEIs) or atypical antipsychotic , modafinil initially had a positive effect , but didn't last long.  memantine improves cognitive function and neuropsychiatric features in patients with DLB.
  • 79.  prion hypothesis - recently
  • 81.  davunetide , tideglusib - failed  droxidopa - orthostatic hypotension – failed  losartan - supine hypertension - failed
  • 82. SUMMARY  Careful clinical examination  AP mimickers  There are currently no biomarkers available.  There are currently no neuroprotective treatments available.  symptomatic and supportive treatments with usually no sustained effect.  Further research required
  • 87. magnetic resonance parkinsonism index (MRPI) -(P / M) x (MCP / SCP) MCP = width of middle cerebellar peduncle SCP = width of superior cerebellar peduncle P = area of pons in midsagittal plane M = area of midbrain in midsagittal plane A value of more than 13.55 indicates an abnormal result, and strongly suggests that these patients will go on to develop PSP.
  • 88. Misdiagnosis PD with AP , as well as FTD,AD,PPA Mimickers of AtypicalPD Eg: SCAS/ FTAX- mimic MSA Neimann Pick C,CTX,prion d/s,mitochondrial- mimic AP phenotype - Age of onset - Tempo of progression - Family history - Clinical exam + associated features